Arcus Biosciences, Inc. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
Terry Rosen (CEO) and Robert C. Goeltz II (CFO) certified the Form 10-Q for the period ending June 30, 2026, filed August 5, 2026. Both officers certified that the report contains no untrue material statements, that financial statements fairly present the company's condition, and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, significant deficiencies, or fraud were disclosed.
Why this rating
Routine Sarbanes-Oxley certifications; standard quarterly filing requirement with no disclosure of control weaknesses.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.